Literature DB >> 8601632

Production of interleukin 1beta by human hematopoietic progenitor cells.

K Watari1, H Mayani, F Lee, W Dragowska, P M Lansdorp, J W Schrader.   

Abstract

The production of interleukin 1beta (IL-1beta) by human hematopoietic stem/progenitor cells was studied to explore the concept that these cells are not merely responders to stimuli from their microenvironment, but can themselves produce a powerful biomodulator. Cells with a CD34+ CD45RA(lo) CD71(lo) phenotype were purified from human umbilical cord blood and cultured one per well in serum-free medium with a mixture of cytokines. Cells that had divided over 2-5 d to form doublets were identified and the daughter cells were studied individually. 91% (460/506) of daughter cells had clonogenic potential. Analysis of these individual daughter cells by reverse transcription-polymerase chain reaction showed that 29% of them (14/48) were positive for IL-1beta mRNA. One of the cells that was strongly positive for IL-1beta mRNA had a sibling that generated 366,000 cells of multiple lineages after 14 d. IL-1beta converting enzyme mRNA, which is necessary to produce IL-1beta, was also detected by reverse transcription-polymerase chain reaction at the single-cell level. Moreover, enzyme immunoassay for mature secreted IL-1beta in culture supernatants demonstrated the production of IL-1beta protein by these cells. This was confirmed by fluorescent immunostaining of the cells for human IL-1beta which showed a significant portion of positive cells. Taken together, the results demonstrate the capacity of early hematopoietic cells to synthesize IL-1beta. The capacity of human hematopoietic stem/progenitor cells to produce IL-1beta may be involved in regulation of their proliferation and differentiation under certain circumstances and dysregulation of this process may be modified in leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601632      PMCID: PMC507231          DOI: 10.1172/JCI118593

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Differentiation in B-precursor acute lymphoblastic leukemia cell populations with CD34-positive subpopulations.

Authors:  G G Re; Z Estrov; G R Antoun; E A Felix; D P Pinkel; T F Zipf
Journal:  Blood       Date:  1991-08-01       Impact factor: 22.113

2.  Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein.

Authors:  B M Curtis; D E Williams; H E Broxmeyer; J Dunn; T Farrah; E Jeffery; W Clevenger; P deRoos; U Martin; D Friend
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

3.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

Review 4.  Differentiation and proliferation of hematopoietic stem cells.

Authors:  M Ogawa
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

5.  Dissociation between interleukin-1 beta mRNA and protein synthesis in human peripheral blood mononuclear cells.

Authors:  R Schindler; B D Clark; C A Dinarello
Journal:  J Biol Chem       Date:  1990-06-25       Impact factor: 5.157

6.  Molecular cloning of the interleukin-1 beta converting enzyme.

Authors:  D P Cerretti; C J Kozlosky; B Mosley; N Nelson; K Van Ness; T A Greenstreet; C J March; S R Kronheim; T Druck; L A Cannizzaro
Journal:  Science       Date:  1992-04-03       Impact factor: 47.728

7.  Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock.

Authors:  P Li; H Allen; S Banerjee; S Franklin; L Herzog; C Johnston; J McDowell; M Paskind; L Rodman; J Salfeld
Journal:  Cell       Date:  1995-02-10       Impact factor: 41.582

8.  Autocrine stimulation of interleukin 1 beta in acute myelogenous leukemia cells.

Authors:  K Sakai; T Hattori; M Matsuoka; N Asou; S Yamamoto; K Sagawa; K Takatsuki
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

9.  Long-term erythropoiesis from constant numbers of CD34+ cells in serum-free cultures initiated with highly purified progenitor cells from human bone marrow.

Authors:  P M Lansdorp; W Dragowska
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Ontogeny-related changes in proliferative potential of human hematopoietic cells.

Authors:  P M Lansdorp; W Dragowska; H Mayani
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  6 in total

1.  Interleukin-1 regulates hematopoietic progenitor and stem cells in the midgestation mouse fetal liver.

Authors:  Claudia Orelio; Marian Peeters; Esther Haak; Karin van der Horn; Elaine Dzierzak
Journal:  Haematologica       Date:  2009-02-19       Impact factor: 9.941

2.  Interleukin-1-mediated hematopoietic cell regulation in the aorta-gonad-mesonephros region of the mouse embryo.

Authors:  Claudia Orelio; Esther Haak; Marian Peeters; Elaine Dzierzak
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

3.  Red Blood Cells Store and Release Interleukin-33.

Authors:  Jianxin Wei; Jing Zhao; Valerie Schrott; Yingze Zhang; Mark Gladwin; Grant Bullock; Yutong Zhao
Journal:  J Investig Med       Date:  2015-08       Impact factor: 2.895

4.  Changes in chromatin structure and methylation of the human interleukin-1beta gene during monopoiesis.

Authors:  Inga Wessels; Daniela Fleischer; Lothar Rink; Peter Uciechowski
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

5.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

6.  SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.

Authors:  Tomasz Rzymski; Michał Mikula; Eliza Żyłkiewicz; Agnieszka Dreas; Katarzyna Wiklik; Aniela Gołas; Katarzyna Wójcik; Magdalena Masiejczyk; Anna Wróbel; Izabela Dolata; Agata Kitlińska; Małgorzata Statkiewicz; Urszula Kuklinska; Krzysztof Goryca; Łukasz Sapała; Aleksandra Grochowska; Aleksandra Cabaj; Małgorzata Szajewska-Skuta; Ewelina Gabor-Worwa; Katarzyna Kucwaj; Arkadiusz Białas; Adam Radzimierski; Michał Combik; Jakub Woyciechowski; Maciej Mikulski; Renata Windak; Jerzy Ostrowski; Krzysztof Brzózka
Journal:  Oncotarget       Date:  2017-05-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.